Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This study found no significant difference in the seroconversion rate of SARS-CoV2 IgG between patients with Immune Mediated Inflammatory diseases undergoing Targeted Immune-Modulating Therapies and those on conventional systemic treatment.

This article discusses the potential of novel microneedle transdermal systems for enhanced drug and vaccine delivery through the skin, but reports no clinical results and emphasizes ongoing trials.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

In this review, summarized findings suggest that emerging targeted immunotherapies may offer promising treatment options for alopecia areata by addressing the breakdown of hair follicle immune privilege.

This study systematically reviewed literature on paradoxical reactions during biologic treatments for psoriasis, identifying immune dysregulation mechanisms and diverse clinical manifestations, highlighting that mild cases often respond well to topical treatments, while severe cases may require switching to different IL-23 inhibitors.

This study found that human hair follicle cells suppress immune activity, with somatostatin playing a significant role, suggesting potential applications for treating inflammatory hair loss conditions.

In this study, the elimination of NG2+ hair follicle stem cells during the anagen phase was associated with an aggravated sensitization phase of allergic contact dermatitis, suggesting their immunosuppressive role.

This study found that IL18 signaling plays a crucial role in the homing and retention of mature regulatory T cells in the mouse thymus, primarily by upregulating the chemokine receptor CCR6.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

This study found that intrathymic injection of recipient-type splenocytes into donor rats, combined with antilymphocyte antiserum, effectively prevented graft-versus-host disease for up to 300 days.

This article reviews current and emerging treatments for alopecia areata, emphasizing the need for biomarker-driven patient stratification to optimize therapeutic strategies and reduce potential side effects; it reports no new clinical findings.

This article discusses the expression and potential new roles of innate immunity genes in CD49f(+) /CD34(+) hair follicle stem cells, but reports no new experimental results.

In this review, the authors discuss how niche-specific immunometabolic regulation influences tissue repair across various organs by highlighting the complex, context-dependent interaction between immune metabolism and tissue-specific regenerative outcomes.

This study found that interleukin-12 signals play a role in hair follicle immune privilege collapse in ex vivo alopecia areata models, and a TYK2 inhibitor may help prevent or reverse this process.

This study found that interleukin-1α and interleukin-7 secreted by keratinocytes enhance the proliferation of γδT-cells and epidermal stem cells, revealing mechanisms of stem cell activation during wound healing in mice.

In a mouse model of alopecia areata, this study found that IL-27 overexpression using an adeno-associated virus protected against disease development, potentially by promoting immunosuppressive T cells and reducing CD8 T cell infiltration into hair follicles.

This article reviews the relationship between the skin and the immune system and discusses how skin manifestations can indicate immunodeficiencies but reports no new research findings.

This study found that anti-CD44 treatment inhibited leukocyte migration in alopecia areata and eczema, suggesting targeted therapies could enhance contact sensitizer treatment for alopecia areata.

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

This article discusses how designing biomaterials to modulate immune responses has become a promising strategy for enhancing tissue repair and regeneration.

This study found that stress increases the number of peptidergic nerve fibers and mast cell activity in mouse skin, suggesting a significant neuro-immune interaction under stress.

Reducing CD8+ T cell growth can stabilize alopecia areata.

This study found that inhibiting the PI3Kδ enzyme in murine models of cutaneous chronic graft-versus-host disease (cGVHD) reduced skin scores and fibrosis, prevented pathogenic lymphoid structures, and improved survival, suggesting it as a promising therapeutic approach to address the disease's hypoxic pathophysiology.

In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.

In this study, a nanoparticle system codelivering diphenylcyclopropenone and rapamycin successfully induced immune tolerance and promoted hair regrowth in a mouse model of alopecia areata, offering a promising new therapeutic strategy for this autoimmune condition.

The authors developed a severe mouse model of chronic graft-versus-host disease and reported that rapamycin treatment improved survival compared to placebo, potentially by promoting regulatory T cell expansion.

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

This review explores the complex, context-dependent roles of tumor-secreted proteins and suggests that some proteins traditionally seen as tumor-promotive may act as tumor-suppressors in different environments, emphasizing the influence of cell fitness and treatment exposure.